



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

# Involving Patients in Oncology Drug Development Overall Views and Expectations

---

**CDDF Multi-Stakeholder Workshop on "Involving Patients in Oncology Drug Development", Amsterdam, The Netherlands**

Presented by Pierre Démolis on 18 June 2019  
Oncology Working Party and SAWP

An agency of the European Union





## Disclaimer

---

These PowerPoint slides are copyright of the European Medicines Agency.

Reproduction is permitted provided the source is acknowledged.

The presenter does not have any conflict of interests.

Personal views expressed here.

---



## Besides Science and Regulatory Science, Does 'Patients' Science Exist ?

How can scientists and regulators take into account... ?

Pain  
Feelings  
Burden  
Fears



Related to

Disease over time  
Treatments and adverse effects  
Social consequences

Development principles and ethics  
How do we define benefits a priori?  
Are clinical trials acceptable and useful?  
Is a given effect of any benefit?  
How acceptable are adverse events ?



## Besides Science and Regulatory Science, Does 'Patients' Science Exist ?



Development principles and ethics  
How do we define benefits a priori?  
Are clinical trials acceptable and useful?  
Is a given effect of any benefit?  
How acceptable are adverse events ?



## Patients? Who's that?

---

- Individuals, Caregivers, Relatives
- Associations, organizations (more than one?)
- Patients-Experts
- At which stage of a given disease ?